Pfizer (NYSE:PFE) Revises FY23 Revenue Guidance To $67B-$70B Vs. Consensus Of $61.01B And Prior Guidance Of $67B-$71B; Adjusts 2023 Non-COVID Operational Revenue Growth Expectation to 6%-8%.
Pfizer (NYSE:PFE) Revises FY23 Revenue Guidance To $67B-$70B Vs. Consensus Of $61.01B And Prior Guidance Of $67B-$71B; Adjusts 2023 Non-COVID Operational Revenue Growth Expectation to 6%-8%.